EMG
AVDL

Ellington Management Group’s Avadel Pharmaceuticals AVDL Stock Holding History

Ellington Management Group’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-15,300
Closed -$169K – 630
2017
Q2 		$169K Buy
+15,300
New +$154K 0.02% 558
2016
Q4 		– Sell
-14,800
Closed -$184K – 547
2016
Q3 		$184K Buy
+14,800
New +$193K 0.05% 558
2015
Q1 		– Sell
-21,900
Closed -$375K – 668
2014
Q4 		$375K Buy
+21,900
New +$313K 0.12% 271

Other funds holding AVDL

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Ellington Management Group's AVDL Position: Q3 2017 in Review

Ellington Management Group sold out of Avadel Pharmaceuticals (AVDL) in Q3 2017, closing a stake of 15,300 shares — an estimated $169K sold.

Ellington Management Group first reported a position in AVDL in Q4 2014 and held it in 3 quarters. The position peaked at $375K in Q4 2014. 82 funds tracked by Wall St. Rank hold AVDL as of Q3 2017.

  • Ellington Management Group reported no remaining Avadel Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Ellington Management Group sold 15,300 Avadel Pharmaceuticals shares in Q3 2017, an estimated $169K.
  • Ellington Management Group first reported a position in Avadel Pharmaceuticals in Q4 2014 and held it in 3 quarters.
  • Ellington Management Group's Avadel Pharmaceuticals position peaked at $375K in Q4 2014.
  • 82 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2017.

Based on Ellington Management Group's 13F filing for Q3 2017, filed 14 Nov 2017.